Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1999 Jan;54(1):7–14. doi: 10.1136/thx.54.1.7

Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis

P M van Grunsven 1, C P van Schayck 1, J Derenne 1, H Kerstjens 1, T Renkema 1, D Postma 1, T Similowski 1, R Akkermans 1, P Jong 1, P Dekhuijzen 1, C L A van Herwaarden 1, C van Weel 1
PMCID: PMC1745350  PMID: 10343624

Abstract

BACKGROUND—The role of inhaled corticosteroids in the long term management of chronic obstructive pulmonary disease (COPD) is still unclear. A meta-analysis of the original data sets of the randomised controlled trials published thus far was therefore performed. The main question was: "Are inhaled corticosteroids able to slow down the decline in lung function (FEV1) in COPD?"
METHODS—A Medline search of papers published between 1983 and 1996 was performed and three studies were selected, two of which were published in full and one in abstract form. Patients with "asthmatic features" were excluded from the original data. Ninety five of the original 140 patients treated with inhaled corticosteroids (81 with 1500 µg beclomethasone daily, six with 1600 µg budesonide daily, and eight with 800 µg beclomethasone daily) and 88 patients treated with placebo (of the initial 144 patients) were included in the analysis. The effect on FEV1 was assessed by a multiple repeated measurement technique in which points of time in the study and treatment effects (inhaled corticosteroids compared with placebo) were investigated.
RESULTS—No baseline differences were observed (mean age 61 years, mean FEV1 45% predicted). The estimated two year difference in prebronchodilator FEV1 was +0.034 l/year (95% confidence interval (CI) 0.005 to 0.063) in the inhaled corticosteroid group compared with placebo. The postbronchodilator FEV1 showed a difference of +0.039 l/year (95% CI -0.006 to 0.084). No beneficial effect was observed on the exacerbation rate. Worsening of the disease was the reason for drop out in four patients in the treatment group compared with nine in the placebo group. In the treatment group six of the 95 subjects dropped out because of an adverse effect which may have been related to the treatment compared with two of the 88 patients in the placebo group.
CONCLUSIONS—This meta-analysis in patients with clearly defined moderately severe COPD showed a beneficial course of FEV1 during two years of treatment with relatively high daily dosages of inhaled corticosteroids.



Full Text

The Full Text of this article is available as a PDF (145.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthonisen N. R., Connett J. E., Kiley J. P., Altose M. D., Bailey W. C., Buist A. S., Conway W. A., Jr, Enright P. L., Kanner R. E., O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497–1505. [PubMed] [Google Scholar]
  2. Dompeling E., van Schayck C. P., van Grunsven P. M., van Herwaarden C. L., Akkermans R., Molema J., Folgering H., van Weel C. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Intern Med. 1993 May 15;118(10):770–778. doi: 10.7326/0003-4819-118-10-199305150-00003. [DOI] [PubMed] [Google Scholar]
  3. Geddes D. M. Inhaled corticosteroids: benefits and risks. Thorax. 1992 Jun;47(6):404–407. doi: 10.1136/thx.47.6.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kerstjens H. A., Brand P. L., Hughes M. D., Robinson N. J., Postma D. S., Sluiter H. J., Bleecker E. R., Dekhuijzen P. N., de Jong P. M., Mengelers H. J. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med. 1992 Nov 12;327(20):1413–1419. doi: 10.1056/NEJM199211123272003. [DOI] [PubMed] [Google Scholar]
  5. Kerstjens H. A., Overbeek S. E., Schouten J. P., Brand P. L., Postma D. S. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Respir J. 1993 Jun;6(6):868–876. [PubMed] [Google Scholar]
  6. Lacoste J. Y., Bousquet J., Chanez P., Van Vyve T., Simony-Lafontaine J., Lequeu N., Vic P., Enander I., Godard P., Michel F. B. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1993 Oct;92(4):537–548. doi: 10.1016/0091-6749(93)90078-t. [DOI] [PubMed] [Google Scholar]
  7. Postma D. S., Peters I., Steenhuis E. J., Sluiter H. J. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J. 1988 Jan;1(1):22–26. [PubMed] [Google Scholar]
  8. Postma D. S., Steenhuis E. J., van der Weele L. T., Sluiter H. J. Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis. 1985 Jul;67(1):56–64. [PubMed] [Google Scholar]
  9. Quanjer P. H., Tammeling G. J., Cotes J. E., Pedersen O. F., Peslin R., Yernault J. C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5–40. [PubMed] [Google Scholar]
  10. Renkema T. E., Schouten J. P., Koëter G. H., Postma D. S. Effects of long-term treatment with corticosteroids in COPD. Chest. 1996 May;109(5):1156–1162. doi: 10.1378/chest.109.5.1156. [DOI] [PubMed] [Google Scholar]
  11. Rutten-van Mölken M. P., Van Doorslaer E. K., Jansen M. C., Kerstjens H. A., Rutten F. F. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995 Apr;151(4):975–982. doi: 10.1164/ajrccm.151.4.7697275. [DOI] [PubMed] [Google Scholar]
  12. Siafakas N. M., Vermeire P., Pride N. B., Paoletti P., Gibson J., Howard P., Yernault J. C., Decramer M., Higenbottam T., Postma D. S. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995 Aug;8(8):1398–1420. doi: 10.1183/09031936.95.08081398. [DOI] [PubMed] [Google Scholar]
  13. Watson A., Lim T. K., Joyce H., Pride N. B. Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. Chest. 1992 Feb;101(2):350–355. doi: 10.1378/chest.101.2.350. [DOI] [PubMed] [Google Scholar]
  14. van Schayck C. P., van Grunsven P. M., Dekhuijzen P. N. Do patients with COPD benefit from treatment with inhaled corticosteroids? Eur Respir J. 1996 Oct;9(10):1969–1972. doi: 10.1183/09031936.96.09101969. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES